Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
IGM Biosciences, Inc. - Common Stock
(NQ:
IGMS
)
1.290
+0.170 (+15.18%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 1, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about IGM Biosciences, Inc. - Common Stock
< Previous
1
2
Next >
IGM Biosciences to Present at Two Upcoming Investor Conferences
May 02, 2023
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Biosciences to Present at the Stifel 2023 Targeted Oncology Days
April 19, 2023
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Biosciences Announces Six Presentations at the American Society for Cancer Research Annual Meeting 2023
April 13, 2023
Presentations highlight data from across all oncology pipeline programs
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 30, 2023
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Biosciences to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on March 30, 2023
March 27, 2023
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Biosciences to Present at the Guggenheim 2023 Oncology Conference
February 02, 2023
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Biosciences Initiates First-in-Human Clinical Trial of IGM-7354 in Solid Tumors
January 17, 2023
– Targeted IL-15/IL-15R IgM antibody to be evaluated for safety and pharmacodynamic effects –
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development
January 09, 2023
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Biosciences Presents Data from T cell Engager Portfolio for Hematologic Malignancies at 2022 American Society of Hematology Annual Meeting
December 11, 2022
First Preclinical Data for IGM-2644 and IGM-2537 Featured in Poster Presentations
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Biosciences to Present at the Bank of America Biotech SMID Cap Conference
December 01, 2022
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Biosciences to Present at Three Upcoming Investor Conferences
November 08, 2022
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Biosciences Announces Third Quarter 2022 Financial Results and Provides Corporate Update
November 03, 2022
From
IGM Biosciences, Inc.
Via
GlobeNewswire
IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgkin’s Lymphoma
November 02, 2022
From
IGM Biosciences, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.